Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valdecoxib does not impair platelet function.

Philip T Leese1, Sheela Talwalker, Jeffrey D Kent

  • 1Quintiles Phase I Services, 11250 Corporate Ave, Lenexa, KS, USA.

The American Journal of Emergency Medicine
|July 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a registry to evaluate immobilized lipase cartridge use in pediatric patients with short bowel syndrome/intestinal failure.

Intestinal Failure (New York, N.Y.)·2026
Same author

Real-World Evidence of Growth Improvement in Children 1 to 5 Years of Age Receiving Enteral Formula Administered Through an Immobilized Lipase Cartridge.

Nutrients·2026
Same author

Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells.

Frontiers in immunology·2024
Same author

New-Onset Gout as an Independent Risk Factor for Returning to Dialysis After Kidney Transplantation.

Transplantation direct·2020
Same author

A Retrospective Cohort Study of the Effect of Gout on Mortality Among Patients with a History of Kidney Transplantation.

Annals of transplantation·2020
Same author

Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplantation Population.

Progress in transplantation (Aliso Viejo, Calif.)·2020
Same journal

Isolated angioedema in the emergency department: rarely an allergic reaction.

The American journal of emergency medicine·2026
Same journal

Diagnostic accuracy of emergency department triage systems for predicting clinical severity: A systematic review and meta-analysis of five-level triage scales.

The American journal of emergency medicine·2026
Same journal

Methanol toxicity from inhalational abuse of a methyl acetate-containing nail polish remover.

The American journal of emergency medicine·2026
Same journal

Regarding strategies, feasibility of implementations and results of HIV screening in emergency departments.

The American journal of emergency medicine·2026
Same journal

Rocuronium dosing for rapid sequence intubation: A retrospective analysis in ED and ICU settings.

The American journal of emergency medicine·2026
Same journal

Clinical features of adults with undiagnosed acute leukemia in the emergency department: A descriptive study.

The American journal of emergency medicine·2026
See all related articles

A supratherapeutic dose of valdecoxib did not affect platelet function, unlike naproxen and diclofenac. This suggests valdecoxib may be a safer analgesic option for patients concerned about bleeding complications.

Area of Science:

  • Pharmacology
  • Hematology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) can affect platelet function.
  • Cyclooxygenase-2 (COX-2) specific inhibitors offer an alternative with potentially fewer gastrointestinal side effects.
  • Understanding the impact of COX-2 inhibitors on platelet function is crucial for patient safety.

Purpose of the Study:

  • To compare the effects of a supratherapeutic dose of valdecoxib with naproxen, diclofenac, and placebo on platelet function.
  • To evaluate the impact on platelet aggregation, bleeding time, and serum thromboxane B2 levels.

Main Methods:

  • A 7.5-day, single-center, randomized, placebo-controlled trial involving 62 healthy adults.
  • Administration of supratherapeutic doses of valdecoxib (40 mg twice daily), naproxen (500 mg twice daily), diclofenac (75 mg twice daily), and placebo.

Related Experiment Videos

  • Measurement of platelet aggregation (arachidonate, collagen, ADP), bleeding time, and serum thromboxane B2 at baseline and regular intervals.

    • Main Results:

    • Valdecoxib showed no significant effect on platelet function.
    • Naproxen and diclofenac significantly reduced platelet aggregation responses compared to placebo.
    • Naproxen significantly lowered serum thromboxane B2 levels.

    Conclusions:

    • A supratherapeutic dose of valdecoxib does not impair platelet function (COX-1 activity).
    • Conventional NSAIDs like naproxen and diclofenac significantly affect platelet aggregation.
    • Valdecoxib may offer a safer analgesic alternative for patients at risk of bleeding complications.